Published in Law and Health Weekly, October 22nd, 2005
Under the agreement, Aradigm will grant the undisclosed company access to its intellectual property specific to the pulmonary delivery of nicotine using its patented AERx technology. This exclusive agreement facilitates ongoing negotiations and research.
"The market for smoking cessation is enormous. Aradigm and our partner intend to develop a new, more effective therapy for smoking cessation," said Bryan Lawlis, Aradigm's president and CEO. "We are pleased that our partner has demonstrated...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.